KR20210024040A - 조합 유전자 요법 - Google Patents

조합 유전자 요법 Download PDF

Info

Publication number
KR20210024040A
KR20210024040A KR1020217001827A KR20217001827A KR20210024040A KR 20210024040 A KR20210024040 A KR 20210024040A KR 1020217001827 A KR1020217001827 A KR 1020217001827A KR 20217001827 A KR20217001827 A KR 20217001827A KR 20210024040 A KR20210024040 A KR 20210024040A
Authority
KR
South Korea
Prior art keywords
transgene
vector
combination therapy
type
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217001827A
Other languages
English (en)
Korean (ko)
Inventor
안달루시 사미르 엘
퍼 룬딘
Original Assignee
에복스 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에복스 테라퓨틱스 리미티드 filed Critical 에복스 테라퓨틱스 리미티드
Publication of KR20210024040A publication Critical patent/KR20210024040A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Manufacturing & Machinery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217001827A 2018-06-22 2019-06-21 조합 유전자 요법 Withdrawn KR20210024040A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1810301.0A GB201810301D0 (en) 2018-06-22 2018-06-22 Combinatorial gene therapy
GB1810301.0 2018-06-22
PCT/EP2019/066471 WO2019243574A1 (en) 2018-06-22 2019-06-21 Combinatorial gene therapy

Publications (1)

Publication Number Publication Date
KR20210024040A true KR20210024040A (ko) 2021-03-04

Family

ID=63042788

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217001827A Withdrawn KR20210024040A (ko) 2018-06-22 2019-06-21 조합 유전자 요법

Country Status (14)

Country Link
US (1) US20210252164A1 (https=)
EP (1) EP3810206B1 (https=)
JP (1) JP2021528407A (https=)
KR (1) KR20210024040A (https=)
CN (1) CN112955185A (https=)
AU (1) AU2019289998A1 (https=)
BR (1) BR112020026260A2 (https=)
CA (1) CA3104432A1 (https=)
GB (1) GB201810301D0 (https=)
IL (1) IL279584A (https=)
MX (1) MX2020013865A (https=)
SG (1) SG11202012727SA (https=)
WO (1) WO2019243574A1 (https=)
ZA (1) ZA202100244B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022315530A1 (en) 2021-07-20 2024-01-18 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273150A1 (en) * 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
CN102813942A (zh) * 2012-08-15 2012-12-12 钟志容 脂质超声微泡介导的腺相关病毒基因转染制剂及制备工艺
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
EP3842537A1 (en) * 2013-12-30 2021-06-30 CureVac AG Artificial nucleic acid molecules
CA2960164A1 (en) * 2014-09-05 2016-03-10 Exerkine Corporation Methods of producing and using exersomes and bioengineered exersomes
WO2016044947A1 (en) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes useful to treat lysosomal storage disease
AU2017241534A1 (en) * 2016-03-28 2018-10-04 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitability
GB2568255A (en) * 2017-11-08 2019-05-15 Evox Therapeutics Ltd Exosomes comprising RNA therapeutics

Also Published As

Publication number Publication date
CA3104432A1 (en) 2019-12-26
JP2021528407A (ja) 2021-10-21
BR112020026260A2 (pt) 2021-03-23
IL279584A (en) 2021-03-01
EP3810206A1 (en) 2021-04-28
ZA202100244B (en) 2022-07-27
GB201810301D0 (en) 2018-08-08
US20210252164A1 (en) 2021-08-19
EP3810206B1 (en) 2024-01-24
SG11202012727SA (en) 2021-01-28
WO2019243574A1 (en) 2019-12-26
AU2019289998A1 (en) 2021-02-04
CN112955185A (zh) 2021-06-11
MX2020013865A (es) 2021-03-25

Similar Documents

Publication Publication Date Title
EP3810206B1 (en) Combinatorial gene therapy
JP2024009845A (ja) 完全ヒト翻訳後修飾抗体による治療剤
JP7208231B2 (ja) 肺組織への標的化薬物及び遺伝子送達のためのシンシチンの使用
JP7381494B2 (ja) 転写調節要素及びその使用
JP6879486B2 (ja) Ｆｖｉｉｉおよびｆｉｘ用の最適化された肝臓特異的発現系
JP2022153418A (ja) 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療
TW201837170A (zh) 新穎ａａｖ媒介的流感疫苗
KR20200086322A (ko) Rna 치료제를 포함하는 엑소좀
JP2019520852A (ja) 治療的ポリペプチドを含むエクソソーム
US12467066B2 (en) Compositions and methods for treating retinal disorders
US20150045416A1 (en) Methods and Compositions for Gene Delivery
CN114072129A (zh) 可用于治疗异染性脑白质营养不良的组合物
CA3078096A1 (en) Use of syncytin for targeting drug and gene delivery to regenerating muscle tissue
JP2023524414A (ja) Ｔｄｐ－４３プロテイノパチーの処置のための組成物および方法
KR20230131223A (ko) 리간드와 생리 활성을 갖는 단백질의 융합 단백질을코딩하는 유전자가 짜넣어진 핵산 분자
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
Evans et al. Selected Oral Presentations
JP2023548632A (ja) アルツハイマー病の処置のための組成物および方法
Lettner et al. Trans-splicing gene therapy in the KRT14 gene
HK40030486A (en) Compositions and methods for treating retinal disorders
HK40030486B (en) Compositions and methods for treating retinal disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220620

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20240318

WITB Written withdrawal of application